Oragenics (OGEN) Research & Development (2010 - 2026)
Oragenics' (OGEN) quarterly Research & Development came in at $645470.0 in Q1 2026, up 88.99% YoY from $341542.0 in Q1 2025, and down 3.74% on a QoQ basis from $670543.0 in Q4 2025.
Oragenics (OGEN) Research & Development (2010 - 2026) Analysis & Trends
Oragenics (OGEN) has 17 years of Research & Development data on file, last reported at $645470.0 in Q1 2026.
- Quarterly Research & Development rose 88.99% year-over-year to $645470.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 28.9% YoY) and the FY2025 annual result came in at $2.4 million, down 41.85% from the prior year.
- Research & Development declined to $645470.0 in Q1 2026, from $670543.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $11.0 million in Q4 2023 to a low of $341542.0 in Q1 2025.
- A 5-year average of $1.9 million and a median of $930894.0 in 2025 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 682.05% — and 2024, when it plunged 84.92%.
- Tracing OGEN's Research & Development over 5 years: stood at $1.4 million in 2022, then surged by 682.05% to $11.0 million in 2023, then sank by 84.92% to $1.7 million in 2024, then sank by 59.73% to $670543.0 in 2025, then dropped by 3.74% to $645470.0 in 2026.
- The last three Research & Development figures came in at $645470.0 (Q1 2026), $670543.0 (Q4 2025), and $930894.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Oragenics | 2.38 Mn | 2.38 Mn | - | 1.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.18 Mn |
| Mar 31, 2026 | 645,470.00 |
| Dec 31, 2025 | 670,543.00 |
| Sep 30, 2025 | 930,894.00 |
| Jun 30, 2025 | 449,679.00 |
| Mar 31, 2025 | 341,542.00 |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | 879,041.00 |
| Jun 30, 2024 | 906,779.00 |
| Mar 31, 2024 | 663,414.00 |
| Dec 31, 2023 | 11.04 Mn |
| Sep 30, 2023 | 769,350.00 |
| Jun 30, 2023 | 2.01 Mn |
| Mar 31, 2023 | 1.67 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 2.78 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | 3.29 Mn |
| Dec 31, 2021 | 1.31 Mn |
| Sep 30, 2021 | 3.55 Mn |